The information published on this website about Tagrisso 80 mg is intended for general educational and informational purposes. It is designed to help readers understand the medicine, its active ingredient, its potential uses, administration considerations, possible adverse reactions and important safety precautions.
This website does not replace a consultation with a qualified healthcare professional, an individualized medical assessment or the official prescribing information supplied for the applicable product. Patients should always consult their oncologist, prescribing clinician or pharmacist regarding questions about their diagnosis, treatment plan, dosage and medication safety.
Tagrisso is a prescription medicine containing osimertinib. It is used in specified clinical settings involving certain forms of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Its suitability depends on the patient’s diagnosis, molecular test results, disease stage, previous treatment and other clinical considerations.
1. Educational Purpose of This Website
The purpose of this website is to present general information about Tagrisso 80 mg in an understandable format. Content may explain the medicine’s active ingredient, mechanism of action, treatment settings, administration, precautions, potential side effects and questions patients may wish to discuss with their healthcare team.
The information is not intended to establish a diagnosis, recommend a particular treatment for an individual, determine eligibility for cancer therapy or replace professional clinical judgment.
Reading this website does not establish a patient–healthcare professional relationship. The content should not be interpreted as a personalized recommendation to start, continue, interrupt or discontinue any medicine.
2. No Substitute for Professional Medical Advice
Cancer treatment decisions are complex and require consideration of individual medical circumstances. A qualified healthcare professional can evaluate relevant medical records, pathology reports, molecular testing results, imaging findings, laboratory results, other medicines and treatment goals.
General information cannot account for every factor that may affect a patient’s treatment. Even when two patients have the same broad cancer diagnosis, their treatment plans may differ because of differences in tumor biology, previous therapy, other medical conditions or treatment response.
Patients should discuss all important treatment decisions with their oncology team. They should not rely exclusively on website content, online discussions, testimonials or information provided by another patient.
3. No Diagnosis or Treatment Guarantee
This website does not diagnose lung cancer or any other medical condition. It does not determine whether a patient has an EGFR mutation or whether osimertinib is appropriate for a particular tumor.
The presence of lung cancer alone does not establish eligibility for Tagrisso. Appropriate molecular testing and clinical assessment are essential when determining whether a targeted medicine is suitable.
No statement on this website should be understood as a promise that Tagrisso will cure cancer, prevent recurrence, extend survival or produce a specific treatment response. Clinical outcomes vary between patients, and some tumors may not respond or may develop resistance during treatment.
4. Prescription and Dosage Disclaimer
Tagrisso 80 mg is a prescription medicine that must be used under appropriate medical supervision. The correct regimen depends on the indication, the applicable prescribing information and the patient’s clinical circumstances.
The usual adult regimen described in official prescribing information is 80 mg taken orally once daily. However, this general information does not establish the correct dose for every patient. A clinician may need to modify or interrupt treatment in response to adverse reactions or other clinical considerations.
Patients must follow their own prescription and the instructions provided with their medicine. They should not independently increase or reduce the dose, take additional tablets, share their medicine with another person or change the treatment schedule without professional advice.
If prescription instructions appear unclear or conflict with the information on the product packaging, patients should contact their pharmacist or prescribing clinician before making a change.
5. Side Effects and Medical Risks
Like other prescription medicines, osimertinib can cause side effects. Commonly reported reactions include diarrhea, rash, dry skin, nail changes and inflammation of the mouth. The nature and severity of adverse reactions vary between individuals.
Important serious risks include interstitial lung disease or pneumonitis, QT prolongation, cardiomyopathy, keratitis and aplastic anemia. Some adverse reactions may require urgent assessment, additional monitoring, treatment interruption or other medical intervention.
Patients should promptly report new or worsening breathing difficulties, persistent cough, significant eye pain or changes in vision, fainting, a rapid or irregular heartbeat, or other concerning symptoms. Severe or rapidly worsening symptoms may require emergency medical care.
The information on this website is not a complete list of possible adverse reactions. Patients should consult the current official patient leaflet and ask their healthcare team about risks that are particularly relevant to them.
6. Drug Interactions and Existing Medical Conditions
Osimertinib may require additional precautions when used with certain medicines or in patients with particular medical conditions. Medication interactions and overlapping adverse-effect risks can affect the safety of a treatment regimen.
Before starting treatment, patients should provide their healthcare professional with a complete list of prescription medicines, nonprescription products, vitamins, supplements and herbal remedies they use. They should also disclose relevant medical history, including heart, lung and eye conditions.
Patients should not begin, stop or change another medicine solely because of information on this website. A pharmacist or prescribing clinician can assess potential interactions and recommend an appropriate course of action.
7. Pregnancy, Breastfeeding and Reproductive Precautions
Pregnancy and breastfeeding require particular medical consideration during osimertinib treatment. The medicine may pose risks to a developing fetus, and precautions concerning pregnancy prevention and breastfeeding should be discussed with the treating healthcare professional.
Patients who are pregnant, planning pregnancy, think they may be pregnant or are breastfeeding should contact their oncology team for individualized guidance. The appropriate advice depends on the current prescribing information and the patient’s circumstances.
This website does not provide individualized reproductive-health recommendations. Patients should not make independent decisions about treatment or contraception based solely on general online information.
8. Product Information and Authenticity Disclaimer
Product names, stated strengths and company information can help identify a medicine, but website descriptions cannot independently establish the authenticity, quality or regulatory status of a specific package.
Patients should examine the information printed on their product packaging, including the medicine name, active ingredient, strength, batch or lot number, expiry date and company details. They should obtain prescription medicines through legitimate supply channels.
A package photograph, printed logo, barcode or QR code is not conclusive proof that a product is genuine. If a product appears damaged, expired, inconsistent with the prescription or otherwise suspicious, patients should not use it until the concern has been assessed by an appropriate pharmacist or authority.
Regulatory approvals, authorized indications, product presentations and supply arrangements may vary between countries. Readers should verify information relevant to their location and the specific product they have been prescribed.
9. Accuracy, Completeness and Changes to Information
Medical knowledge, regulatory requirements, product labeling and treatment recommendations can change. Although website content may be prepared with the intention of providing useful educational information, this website cannot guarantee that every statement is complete, current or applicable to every jurisdiction and clinical circumstance.
Readers should use the official prescribing information for their product and consult qualified healthcare professionals when making treatment decisions. If a discrepancy exists between general website information and the current official product information or the instructions of the treating clinician, the discrepancy should be clarified with a qualified professional.
The absence of a particular warning, interaction, adverse reaction or precaution from a page does not mean that the issue is unimportant or impossible.
10. External Sources and Third-Party Information
References to manufacturers, medicine classifications, medical terminology or treatment concepts are provided to support general understanding. Such references should not be interpreted as an endorsement of a particular supplier, pharmacy, treatment provider or commercial service.
The inclusion of a company name does not establish that the company manufactures, distributes or authorizes every product described on this website. The responsible organization for a particular product should be confirmed using the applicable packaging and regulatory documentation.
Any statements made by third parties, including testimonials and personal treatment experiences, may not reflect the experiences or likely outcomes of other patients.
11. No Emergency Medical Service
This website is not an emergency medical service and cannot assess urgent symptoms or provide real-time clinical monitoring.
Patients experiencing severe shortness of breath, chest pain, fainting, serious allergic symptoms, sudden vision changes or other potentially life-threatening symptoms should seek immediate local emergency assistance.
Patients should not delay medical care while searching for information online, waiting for a website response or attempting to determine whether a symptom is related to their medicine.
12. Patient Responsibility and Informed Decisions
Patients can support safer treatment by maintaining accurate medication records, attending scheduled appointments, following prescribed instructions and reporting adverse reactions promptly.
They should ask questions when they do not understand a prescription, product label, monitoring plan or treatment recommendation. They should also inform their healthcare team about changes in their health and any new medicines or supplements.
Online educational resources can help patients prepare for clinical discussions, but the final treatment plan must be based on professional assessment and the patient’s individual circumstances.
13. Limitation of Website Information
To the extent permitted by applicable law, the website’s educational content should not be interpreted as a warranty of medical accuracy, product availability, treatment suitability or clinical outcomes. Nothing in this disclaimer is intended to remove any rights or protections that cannot legally be excluded.
The website does not guarantee that the information will meet every reader’s needs or address every possible medical situation. Readers remain responsible for seeking appropriate professional advice and following the instructions applicable to their prescribed medicine.
Final Disclaimer Statement
Tagrisso 80 mg contains osimertinib, a prescription targeted anticancer medicine used in specific clinical settings involving EGFR-mutated non-small cell lung cancer. Its use requires appropriate medical assessment, a valid prescription and ongoing professional supervision.
The information provided on this website is intended to support general understanding, not to replace diagnosis, prescribing decisions, official product information or direct medical care.
Always consult a qualified healthcare professional before making decisions about Tagrisso 80 mg. Follow the instructions provided with your prescribed product and seek urgent medical care for serious or rapidly worsening symptoms.